The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

BioMérieux announced on Friday that it has obtained the CE mark for two immunoassays to detect Chikungunya virus infection.

Mindray plans to distribute a cash dividend of 4.23 billion CNY. Hybribio plans to invest 1.512 billion CNY to build Medical Science Park. USCI completed hundreds of millions of CNY of financing and accelerated to lead the early screening track of liquid biopsy and women's health.

Danaher subsidiary Cepheid announced on Thursday that its Xpert Xpress CoV-2 plus test has received Emergency Use Authorization from the US Food and Drug Administration.

Becton Dickinson has received 510(k) clearance from the US Food and Drug Administration for the MX molecular diagnostics module along with a triplex assay for chlamydia, gonorrhea, and trichomonas.

Spatial proteomics firm Ionpath said on Wednesday that it has received a strategic investment of undisclosed size from Thermo Fisher Scientific.

Qiagen said on Wednesday that it has acquired a 96 percent stake in Blirt, a Gdansk, Poland-based manufacturer of recombinant enzymes for the life science industry.

According to industry insiders, Mindray became the general agent of GenSure Biotech Inc., and officially started entered the SARS-CoV-2 antigen test business.

On May 10, 2022, Guangzhou LBP Medicine Science & Technology Co.,Ltd (688393.SH) and Huawei signed a cooperation agreement in Guangzhou to officially join the Ascend partner program, and also held a solution workshop on pathology data and arithmetic ecology cooperation.

Hologic announced on Tuesday that its Aptima CMV Quant assay for cytomegalovirus has been approved by the US Food and Drug Administration.

OraSure Technologies reported after the close of the market on Tuesday that its first quarter revenues increased 16 percent year over year driven by 21 percent growth in non-COVID revenues.